2008 Vol. 35 No. 03
2008, 35(03): 153-156.
DOI: 10.3971/j.issn.1000-8578.1844
Abstract：
Objective To investigate the antitumor effect of dendritic cell vaccine loaded with the human lung cancer associated antigens. Methods The monocytes were separated f rom human umbilicus cord blood cells and cultured for dendritic cells (UbDC) with rhGM2CSF, rhIL24 and rhTNF2αin RPMI 1640 medium. The human lung cancer cells A549 cytolysis antigen and L PS were added into the medium. Suc2 cessively for loading the A549 antigen on UbDC and promoting DCs mature. The mature DC vaccine loaded with A549 cytolysis antigen (UbDC/ AgL) was sorted by magnetic beads. MTT assay was em2 ployed to test the auto mix lymphocyte reaction (AMLR) . LDH release assay was carried out to assess the killing ability of CTL cells against A549 lung cancer cells. The level of human IL21, IL212, IL26 and TNF2βin the culture supernatant was determined by EL ISA. Results The level of human IL21, IL212, IL26 and TNF2βin the culture supernatant of UbDC/ AgL were higher than that of UbDC/ Ag and UbDC separately( P < 0. 01) . The special CTL cells had significant cytotoxicity against A549 cells ( P < 0. 01) and inducemented lymphopoiesis availability. Conclusion The dendritic cell vaccine loaded with tumor cytolysis antigen can activate naive T lymphocyte and induce specific antitumor immune response efficien2 cy.
Objective To investigate the antitumor effect of dendritic cell vaccine loaded with the human lung cancer associated antigens. Methods The monocytes were separated f rom human umbilicus cord blood cells and cultured for dendritic cells (UbDC) with rhGM2CSF, rhIL24 and rhTNF2αin RPMI 1640 medium. The human lung cancer cells A549 cytolysis antigen and L PS were added into the medium. Suc2 cessively for loading the A549 antigen on UbDC and promoting DCs mature. The mature DC vaccine loaded with A549 cytolysis antigen (UbDC/ AgL) was sorted by magnetic beads. MTT assay was em2 ployed to test the auto mix lymphocyte reaction (AMLR) . LDH release assay was carried out to assess the killing ability of CTL cells against A549 lung cancer cells. The level of human IL21, IL212, IL26 and TNF2βin the culture supernatant was determined by EL ISA. Results The level of human IL21, IL212, IL26 and TNF2βin the culture supernatant of UbDC/ AgL were higher than that of UbDC/ Ag and UbDC separately( P < 0. 01) . The special CTL cells had significant cytotoxicity against A549 cells ( P < 0. 01) and inducemented lymphopoiesis availability. Conclusion The dendritic cell vaccine loaded with tumor cytolysis antigen can activate naive T lymphocyte and induce specific antitumor immune response efficien2 cy.
2008, 35(03): 157-160.
DOI: 10.3971/j.issn.1000-8578.1843
Abstract：
Objective To explore the role of p38 in multicellular spheroid' s chemoresistance of ovarian cancer. Methods Const ruct eukaryotic p38 expression vector of full2length, t ransfect the vector, stably screen and culture it to form three dimensional multi2spheroids. The technique of RT2PCR and Western blot were applied to detect the expression of p38. Af ter the t ransfection of p38, we took the methods FACS and CCK28 to evaluate the sensitivity to cisplatin. Results (1) The expression of p38 was higher in A2780 monolayer cells than in it s multicellular spheroids. (2) When t reated with cisplatin, the apop2 tosis rate of spheroid t ransfected with p38 is higher than it s counterpart s by FACS. (3) The result s of CCK28 (Cell Counting Kit28) were similar to FACS ( P < 0. 05) . Conclusion p38 mediates the cisplatin effect s of ovarian cancer, and the up2regulation of p38 could increase the sensitivity of ovarian MCS to cisplatin.
Objective To explore the role of p38 in multicellular spheroid' s chemoresistance of ovarian cancer. Methods Const ruct eukaryotic p38 expression vector of full2length, t ransfect the vector, stably screen and culture it to form three dimensional multi2spheroids. The technique of RT2PCR and Western blot were applied to detect the expression of p38. Af ter the t ransfection of p38, we took the methods FACS and CCK28 to evaluate the sensitivity to cisplatin. Results (1) The expression of p38 was higher in A2780 monolayer cells than in it s multicellular spheroids. (2) When t reated with cisplatin, the apop2 tosis rate of spheroid t ransfected with p38 is higher than it s counterpart s by FACS. (3) The result s of CCK28 (Cell Counting Kit28) were similar to FACS ( P < 0. 05) . Conclusion p38 mediates the cisplatin effect s of ovarian cancer, and the up2regulation of p38 could increase the sensitivity of ovarian MCS to cisplatin.
2008, 35(03): 161-163.
DOI: 10.3971/j.issn.1000-8578.1840
Abstract：
Objective To investigate the potential effect s of resistin2132peptides on the growth and apopto2 sis in human breast carcinoma cells, MCF27. Methods Basing on the deduced amino2acide sequence f rom the cDNA, a peptide of human resistin molecule, consisting of 13 amino2acide (CSMEEAINERIQE) was synthesized. 32(4, 52Dimethyl222thiazolyl)2 2, 52diphenyl22 H2tet razolium bromide (MTT) assay was used to assess the proliferation effect s of resistin2132peptides. The apoptosis was investigated by the flow cy2 tometer, FCM. Results With the Resistin2132peptides t reatment of 50 、500 、5 000 and 10 000 ng/ ml, the inhibitory rate was 46 % to 92 %. The discrepancy between test and cont rol group s is statistically signifi2 cant ( P < 0. 01) . The apoptotic rate was 6. 7 %、6. 9 %、7. 5 % and 9. 8 % respectively. And the rate of cont rol group was 0. 6 % ( P < 0. 01) . Conclusion Resistin2132peptides can inhibit the proliferation of the cell proliferation and promote the apoptosis of the cells.
Objective To investigate the potential effect s of resistin2132peptides on the growth and apopto2 sis in human breast carcinoma cells, MCF27. Methods Basing on the deduced amino2acide sequence f rom the cDNA, a peptide of human resistin molecule, consisting of 13 amino2acide (CSMEEAINERIQE) was synthesized. 32(4, 52Dimethyl222thiazolyl)2 2, 52diphenyl22 H2tet razolium bromide (MTT) assay was used to assess the proliferation effect s of resistin2132peptides. The apoptosis was investigated by the flow cy2 tometer, FCM. Results With the Resistin2132peptides t reatment of 50 、500 、5 000 and 10 000 ng/ ml, the inhibitory rate was 46 % to 92 %. The discrepancy between test and cont rol group s is statistically signifi2 cant ( P < 0. 01) . The apoptotic rate was 6. 7 %、6. 9 %、7. 5 % and 9. 8 % respectively. And the rate of cont rol group was 0. 6 % ( P < 0. 01) . Conclusion Resistin2132peptides can inhibit the proliferation of the cell proliferation and promote the apoptosis of the cells.
2008, 35(03): 164-168.
DOI: 10.3971/j.issn.1000-8578.1841
Abstract：
Objective To investigate effect of peroxisome proliferator2activated receptorγ( PPARγ) ligand Ciglitazone on proliferation of human gast ric carcinoma MGC803 cells and it s mechanism. Methods To examine PPARγmRNA of MGC803 cells by RT2PCR. To examine effect of PPARγligand Ciglitazone on MGC803 cells proliferation and apoptosis by MTT and Flow Cytomet ry. To examine morphological change of apoptosis by phase cont rast microscope and Hoechst33342 staining. To examine the expression and change of PPARγ,Bcl22, Bag21 and Bax protein of MGC803 cells by immunohistochemist ry and Flow Cytomet ry. Results Ciglitazone (5μmol/ L 、10μmol/ L 、20μmol/ L and 50μmol/ L) inhibited proliferation and induced apoptosis of MGC803 cells and apoptosis is parallel to proliferation inhibition in MGC803 cells, which were dose2 and time2dependent . PPARγmRNA and protein expression, Bax protein expres2 sion and Bax protein over Bcl22 protein ratio were enhanced and both Bcl22 and Bag21 protein expression were decreased with prolonged time following 20μmol/ L Ciglitazone t reatment in MGC803 cells. Conclu2 sion Ciglitazone may inhibit proliferation and induce apoptosis in human gast ric carcinoma MGC803 cells via activating PPARγ. Elevated Bax protein expression and Bax protein over Bcl22 protein ratio and de2 creased Bcl22 and Bag21 protein expression may play an important role during apoptosis of human gast ric carcinoma MGC803 cells induced by Ciglitazone, which suggest that Ciglitazone may effective to t reat gas2 t ric carcinoma.
Objective To investigate effect of peroxisome proliferator2activated receptorγ( PPARγ) ligand Ciglitazone on proliferation of human gast ric carcinoma MGC803 cells and it s mechanism. Methods To examine PPARγmRNA of MGC803 cells by RT2PCR. To examine effect of PPARγligand Ciglitazone on MGC803 cells proliferation and apoptosis by MTT and Flow Cytomet ry. To examine morphological change of apoptosis by phase cont rast microscope and Hoechst33342 staining. To examine the expression and change of PPARγ,Bcl22, Bag21 and Bax protein of MGC803 cells by immunohistochemist ry and Flow Cytomet ry. Results Ciglitazone (5μmol/ L 、10μmol/ L 、20μmol/ L and 50μmol/ L) inhibited proliferation and induced apoptosis of MGC803 cells and apoptosis is parallel to proliferation inhibition in MGC803 cells, which were dose2 and time2dependent . PPARγmRNA and protein expression, Bax protein expres2 sion and Bax protein over Bcl22 protein ratio were enhanced and both Bcl22 and Bag21 protein expression were decreased with prolonged time following 20μmol/ L Ciglitazone t reatment in MGC803 cells. Conclu2 sion Ciglitazone may inhibit proliferation and induce apoptosis in human gast ric carcinoma MGC803 cells via activating PPARγ. Elevated Bax protein expression and Bax protein over Bcl22 protein ratio and de2 creased Bcl22 and Bag21 protein expression may play an important role during apoptosis of human gast ric carcinoma MGC803 cells induced by Ciglitazone, which suggest that Ciglitazone may effective to t reat gas2 t ric carcinoma.
2008, 35(03): 169-172.
DOI: 10.3971/j.issn.1000-8578.1838
Abstract：
Objective To explore the effect of arsenic t rioxide (As2O3 ) in inhibition of proliferation、induc2 tion of apoptosis and it s potential mechanism. Methods The growth inhibition of As2O3 on FU97 was de2 termined by MTT assay. Apoptosis of FU97 induced by As2 O3 was investigated by DNA gel elect ro2 phore. The cell cycle alteration and apoptotic rate of the cells were measured by flow cytomet ry. The ex2 pressions of AFP、VEGF、STAT3 were determined by chemist ryluminescence 、Real2time PCR and EL ISA. Results The inhibitory effect of As2O3 on proliferation of FU97 cells was significant as revealed by MTT. DNA gel elect rophore show a marked DNA ladder. A typical sub2diploid peak before G0 / G1 phase was observed by flow cytomet ry. The effect of As2O3 on FU97 showed a remarkable cell cycle spe2 cificity, which indicates that As2 O3 mainly act s in G2/ M phase. Chemist ryluminescence, Real2time PCR and EL ISA showed As2O3 could obviously decrease AFP、VEGF and STAT3 protein production in FU97 cells. Conclusion As2 O3 can inhibit FU97 cells growth via apoptosis induction and cell cycle arrest . As2O3 inhibit s the metastasis of alpha2fetoprotein2producing gast ric carcinoma through reducing the ex2 pression of AFP、VEGF and STAT3.
Objective To explore the effect of arsenic t rioxide (As2O3 ) in inhibition of proliferation、induc2 tion of apoptosis and it s potential mechanism. Methods The growth inhibition of As2O3 on FU97 was de2 termined by MTT assay. Apoptosis of FU97 induced by As2 O3 was investigated by DNA gel elect ro2 phore. The cell cycle alteration and apoptotic rate of the cells were measured by flow cytomet ry. The ex2 pressions of AFP、VEGF、STAT3 were determined by chemist ryluminescence 、Real2time PCR and EL ISA. Results The inhibitory effect of As2O3 on proliferation of FU97 cells was significant as revealed by MTT. DNA gel elect rophore show a marked DNA ladder. A typical sub2diploid peak before G0 / G1 phase was observed by flow cytomet ry. The effect of As2O3 on FU97 showed a remarkable cell cycle spe2 cificity, which indicates that As2 O3 mainly act s in G2/ M phase. Chemist ryluminescence, Real2time PCR and EL ISA showed As2O3 could obviously decrease AFP、VEGF and STAT3 protein production in FU97 cells. Conclusion As2 O3 can inhibit FU97 cells growth via apoptosis induction and cell cycle arrest . As2O3 inhibit s the metastasis of alpha2fetoprotein2producing gast ric carcinoma through reducing the ex2 pression of AFP、VEGF and STAT3.
2008, 35(03): 173-176.
DOI: 10.3971/j.issn.1000-8578.1839
Abstract：
Objective To study the effect of adenovirus (Ad) mediated double suicide gene driven by KDR promoter on proliferation and apoptosis of human colorectal cancer LOVO cells. Methods The KDR producing cells LOVO and the KDR nonproducing cells LS174 T were infected by the AdEasy2KDR2CDg2 lyTK respectively, followed by t reatment with 52FC and GCV. killing effect s of this suicide gene system on colorectal cancer cells were evaluated. Moreover, the dist ribution of cell cycle was detected by flow cytomet ric assay and pathological character of cells was observed by elect ron microscopy. Results The infection rate of the resultant recombinant Ad ( rAd) to all the cells had not apparently different, and it in2 creased gradually with the addition of multiple of infection (MOI) of Ads. The infected cells exhibited dif2 ferent sensibility to the two prodrugs : LOVO cells infected with rAd were sensitive highly to the pro2 drugs, but the LS174 T cells infected with rAd appeared to be unsensitive to the two prodrugs ( P <0. 001) . The killing effect of CD/ TKfusion gene on the target cells was much st ranger than that of each single suicide gene ( P < 0. 001), and they all had considerable bystander effect . In addition, the cell cycle of LOVO cells was arrested at S phase and morphologic features of apoptosis and necrosis in LOVO cells were displayed via elect ron microscopy. Conclusion The CD/ TK fusion gene system cont rolled by KDR promoter has selectively killing effect on the KDR2CDglyTKexpressing LOVO cells, the mechanism of which may involve the halting the cell cycles and cytotoxic necrosis and apoptosis of cell.
Objective To study the effect of adenovirus (Ad) mediated double suicide gene driven by KDR promoter on proliferation and apoptosis of human colorectal cancer LOVO cells. Methods The KDR producing cells LOVO and the KDR nonproducing cells LS174 T were infected by the AdEasy2KDR2CDg2 lyTK respectively, followed by t reatment with 52FC and GCV. killing effect s of this suicide gene system on colorectal cancer cells were evaluated. Moreover, the dist ribution of cell cycle was detected by flow cytomet ric assay and pathological character of cells was observed by elect ron microscopy. Results The infection rate of the resultant recombinant Ad ( rAd) to all the cells had not apparently different, and it in2 creased gradually with the addition of multiple of infection (MOI) of Ads. The infected cells exhibited dif2 ferent sensibility to the two prodrugs : LOVO cells infected with rAd were sensitive highly to the pro2 drugs, but the LS174 T cells infected with rAd appeared to be unsensitive to the two prodrugs ( P <0. 001) . The killing effect of CD/ TKfusion gene on the target cells was much st ranger than that of each single suicide gene ( P < 0. 001), and they all had considerable bystander effect . In addition, the cell cycle of LOVO cells was arrested at S phase and morphologic features of apoptosis and necrosis in LOVO cells were displayed via elect ron microscopy. Conclusion The CD/ TK fusion gene system cont rolled by KDR promoter has selectively killing effect on the KDR2CDglyTKexpressing LOVO cells, the mechanism of which may involve the halting the cell cycles and cytotoxic necrosis and apoptosis of cell.
2008, 35(03): 177-180.
DOI: 10.3971/j.issn.1000-8578.1836
Abstract：
Objective To study the effect s of Zoledronic acid on expression and secretion of VEGF in os2 teosarcoma LM8 cell line. Methods Af ter LM8 cells were t reated with Zoledronic acid, Semi2quantita2 tive PCR method was used to assess the expression of VEGF mRNA ; the expression and secretion of VEGF protein was detected by immunohistochemical staining and EL ISA respectively. Results The t ranscription of VEGF mRNA, expression and secretion of VEGF protein were found in LM8 cells. The t ranscription of VEGF mRNA, expression and secretion VEGF protein down2regulated by t reatment with 25μmol/ L, 50μmol/ L zoledronic acid for 24h and the effect s had a dose dependent relationship ( P <0. 05) . Conclusion Zoledronic acid can inhibit VEGF mRNA t ranscription, protein expression and secre2 tion in osteosarcoma LM8 cell line.
Objective To study the effect s of Zoledronic acid on expression and secretion of VEGF in os2 teosarcoma LM8 cell line. Methods Af ter LM8 cells were t reated with Zoledronic acid, Semi2quantita2 tive PCR method was used to assess the expression of VEGF mRNA ; the expression and secretion of VEGF protein was detected by immunohistochemical staining and EL ISA respectively. Results The t ranscription of VEGF mRNA, expression and secretion of VEGF protein were found in LM8 cells. The t ranscription of VEGF mRNA, expression and secretion VEGF protein down2regulated by t reatment with 25μmol/ L, 50μmol/ L zoledronic acid for 24h and the effect s had a dose dependent relationship ( P <0. 05) . Conclusion Zoledronic acid can inhibit VEGF mRNA t ranscription, protein expression and secre2 tion in osteosarcoma LM8 cell line.
2008, 35(03): 181-183.
DOI: 10.3971/j.issn.1000-8578.1837
Abstract：
Objective To investigate the protein expressions and relationship of P2gp, GST2π and Topo Ⅱin breast cancer and their lymph2node metastasis tumor. Methods High sensitive SP immunohistochemi2 cal method was used to detect the protein expressions of P2gp, GST2πand Topo Ⅱin 70 breast cancers and their lymph2node metastasis tumors (36 with lymphatic metastasis) . Results (1) The expressions of P2 gp, GST2πin breast cancers with lymphatic metastasis was higher than those without lymphatic metasta2 sis ( P = 0. 043, P = 0. 012), but the expression of Topo Ⅱ had no difference between the two groups. (2) The expressions of GST2π、To Po Ⅱwere significantly associated with lymphatic metastasis ( P = 0. 001, P = 0. 01) . However, the expression of P2gp was not associated with lymphatic metastasis. Conclusion (1) There was a significant relationship between the higher expression of P2gp, GST2π and the axillary lymph node involvement . (2) The drug2resistance of breast cancers was not as same as their lymph2node metastatic tumors.
Objective To investigate the protein expressions and relationship of P2gp, GST2π and Topo Ⅱin breast cancer and their lymph2node metastasis tumor. Methods High sensitive SP immunohistochemi2 cal method was used to detect the protein expressions of P2gp, GST2πand Topo Ⅱin 70 breast cancers and their lymph2node metastasis tumors (36 with lymphatic metastasis) . Results (1) The expressions of P2 gp, GST2πin breast cancers with lymphatic metastasis was higher than those without lymphatic metasta2 sis ( P = 0. 043, P = 0. 012), but the expression of Topo Ⅱ had no difference between the two groups. (2) The expressions of GST2π、To Po Ⅱwere significantly associated with lymphatic metastasis ( P = 0. 001, P = 0. 01) . However, the expression of P2gp was not associated with lymphatic metastasis. Conclusion (1) There was a significant relationship between the higher expression of P2gp, GST2π and the axillary lymph node involvement . (2) The drug2resistance of breast cancers was not as same as their lymph2node metastatic tumors.
2008, 35(03): 184-187.
DOI: 10.3971/j.issn.1000-8578.1835
Abstract：
Objective To investigate the expression of autophagy related Beclin1 gene in human nonsmall2 cell lung cancer tissues. Methods Protein expression of Beclin1 was determined by immunofluorescence staining and Western Blot, mRNA expression were analyzed by RT2PCR. Results Immunofluorescence staining revealed that the levels of Beclin1 expression in lung cancer were significantly lower than those in adjacent noncancerous tissues and normal tissues, the expression rate was 8. 3 % ( P = 0. 000) . The Beclin1 mRNA expression in lung cancer 、adjacent noncancerous tissues、normal tissues were 1. 302 ±0. 074 、1. 691 ±0. 100 、1. 673 ±0. 081 ( F = 6. 6, P = 0. 002) . Beclin1 protein expression in lung cancer 、around cancer tissues、normal tissues were 3. 489 ±0. 293 、5. 306 ±0. 459 、6. 329 ±0. 580 ( F = 9. 73, P < 0. 01) . There was no dependability among the Beclin1 expression and pathology or clinic stage of lung cancer. Conclusion The protein and mRNA expression of Beclin1 in lung cancer were much lower than in adja2 cent noncancerous tissues and normal tissues, those differences were statistical significance, but in adja2 cent noncancerous tissues and normal tissues, the expression were proximal.
Objective To investigate the expression of autophagy related Beclin1 gene in human nonsmall2 cell lung cancer tissues. Methods Protein expression of Beclin1 was determined by immunofluorescence staining and Western Blot, mRNA expression were analyzed by RT2PCR. Results Immunofluorescence staining revealed that the levels of Beclin1 expression in lung cancer were significantly lower than those in adjacent noncancerous tissues and normal tissues, the expression rate was 8. 3 % ( P = 0. 000) . The Beclin1 mRNA expression in lung cancer 、adjacent noncancerous tissues、normal tissues were 1. 302 ±0. 074 、1. 691 ±0. 100 、1. 673 ±0. 081 ( F = 6. 6, P = 0. 002) . Beclin1 protein expression in lung cancer 、around cancer tissues、normal tissues were 3. 489 ±0. 293 、5. 306 ±0. 459 、6. 329 ±0. 580 ( F = 9. 73, P < 0. 01) . There was no dependability among the Beclin1 expression and pathology or clinic stage of lung cancer. Conclusion The protein and mRNA expression of Beclin1 in lung cancer were much lower than in adja2 cent noncancerous tissues and normal tissues, those differences were statistical significance, but in adja2 cent noncancerous tissues and normal tissues, the expression were proximal.
2008, 35(03): 188-190.
DOI: 10.3971/j.issn.1000-8578.1834
Abstract：
Objective To investigate the expression of Ezrin and CD44 and their correlations with clinical2 pathological parameters in gast ric carcinoma. Methods The expression of Ezrin and CD44 in 50 speci2 mens of gast ric carcinoma, 25 specimens of gast ric epithelial dysplasia and 25 specimens of normal gast ric tissues were detected by immunohistochemist ry method. Results ①In normal gast ric tissues, gast ric dysplasia and gast ric carcinoma, the percentage of Ezrin positive expression was 28. 0 %, 36. 0 % and 86. 0 %, respectively, the percentage of CD44 expression was 0, 16. 0 % and 60. 0 %. The expression of Ezrin and CD44 increased gradually in normal gast ric tissues, gast ric dysplasia and gast ric carcinoma. The difference has a statiftical significance ( P < 0. 05) . ②The expression of both Ezrin and CD44 was correlated to clinical stage, metastasis of lymph node, and there were substantial differences ( P < 0. 01), but theses were not correlated to carcinoma differentiation ( P > 0. 05) . ③ The expression of Ezrin was positively correlated to that of CD44 in gast ric carcinoma ( P < 0. 01) . Conclusion The expression of Ezrin and CD44 was correlated to clinical stage and metastasis of lymph node. Joint examination of these two parameters is useful for forecast metastasis and prognosis of gast ric carcinoma.
Objective To investigate the expression of Ezrin and CD44 and their correlations with clinical2 pathological parameters in gast ric carcinoma. Methods The expression of Ezrin and CD44 in 50 speci2 mens of gast ric carcinoma, 25 specimens of gast ric epithelial dysplasia and 25 specimens of normal gast ric tissues were detected by immunohistochemist ry method. Results ①In normal gast ric tissues, gast ric dysplasia and gast ric carcinoma, the percentage of Ezrin positive expression was 28. 0 %, 36. 0 % and 86. 0 %, respectively, the percentage of CD44 expression was 0, 16. 0 % and 60. 0 %. The expression of Ezrin and CD44 increased gradually in normal gast ric tissues, gast ric dysplasia and gast ric carcinoma. The difference has a statiftical significance ( P < 0. 05) . ②The expression of both Ezrin and CD44 was correlated to clinical stage, metastasis of lymph node, and there were substantial differences ( P < 0. 01), but theses were not correlated to carcinoma differentiation ( P > 0. 05) . ③ The expression of Ezrin was positively correlated to that of CD44 in gast ric carcinoma ( P < 0. 01) . Conclusion The expression of Ezrin and CD44 was correlated to clinical stage and metastasis of lymph node. Joint examination of these two parameters is useful for forecast metastasis and prognosis of gast ric carcinoma.
2008, 35(03): 191-193.
DOI: 10.3971/j.issn.1000-8578.1833
Abstract：
Objective To study the correlation of EGFR、c2erbB22 and VEGF expression in colorectal car2 cinoma and their significances to clinicopathological character. Methods We studied the expression level of EGFR、c2erbB22 and VEGF in 61 cases of colorectal carcinoma by Envision method and analysed the correlation of the expression level and colorectal carcinoma clinicopathological character by Multiple linear regression. Results The respectively high expression rate of EGFR、c2erbB22 and VEGF was 49. 2 %, 73. 8 % and 70. 5 %. Multiple linear regression shows that the high expression of EGFR、c2erbB22 and VEGF were related with the tumor size 、lymph nodes metastasis、liver metastasis and Dukes' stages, but not correlated with gender and age. Conclusion The result s suggest that the high expression of EGFR、c2erbB22 and VEGF is an useful tool for providing information about the malignant degree, prognosis, and may be as a gaiding in postoperative chemotherapy selection for patient s with colorectal carcinoma.
Objective To study the correlation of EGFR、c2erbB22 and VEGF expression in colorectal car2 cinoma and their significances to clinicopathological character. Methods We studied the expression level of EGFR、c2erbB22 and VEGF in 61 cases of colorectal carcinoma by Envision method and analysed the correlation of the expression level and colorectal carcinoma clinicopathological character by Multiple linear regression. Results The respectively high expression rate of EGFR、c2erbB22 and VEGF was 49. 2 %, 73. 8 % and 70. 5 %. Multiple linear regression shows that the high expression of EGFR、c2erbB22 and VEGF were related with the tumor size 、lymph nodes metastasis、liver metastasis and Dukes' stages, but not correlated with gender and age. Conclusion The result s suggest that the high expression of EGFR、c2erbB22 and VEGF is an useful tool for providing information about the malignant degree, prognosis, and may be as a gaiding in postoperative chemotherapy selection for patient s with colorectal carcinoma.
2008, 35(03): 194-195.
DOI: 10.3971/j.issn.1000-8578.3345
Abstract：
Objective To investigate the expression and significance of DNA damage2inducible t ranscript 3 (DDIT3) in benign and malignant follicular thyroid tumors. Methods The expression of DDIT3 in 24 ca2 ses of follicular thyroid adenoma ( FTA) and 44 cases of follicular thyroid carcinoma ( FTC) was detected by immunohistochemist rical Envision method. Results The positive rates for DDIT3 in FTA and FTC were 20. 8 % and 93. 2 % respectively, there was significant difference between them ( P < 0. 001) . More2 over, 10 cases of paracarcinomatous tissue were observed, there was no or week expression of DDIT3. Conclusion DDIT3 may be used as a marker for differentiating FTC and FTA.
Objective To investigate the expression and significance of DNA damage2inducible t ranscript 3 (DDIT3) in benign and malignant follicular thyroid tumors. Methods The expression of DDIT3 in 24 ca2 ses of follicular thyroid adenoma ( FTA) and 44 cases of follicular thyroid carcinoma ( FTC) was detected by immunohistochemist rical Envision method. Results The positive rates for DDIT3 in FTA and FTC were 20. 8 % and 93. 2 % respectively, there was significant difference between them ( P < 0. 001) . More2 over, 10 cases of paracarcinomatous tissue were observed, there was no or week expression of DDIT3. Conclusion DDIT3 may be used as a marker for differentiating FTC and FTA.
2008, 35(03): 196-200.
DOI: 10.3971/j.issn.1000-8578.3346
Abstract：
Objective To investigate the change of cytokines in plasma af ter int ravenous chemotherapy in patient s with digestive t ract cancer and to discuss it s clinical significance. Methods Using EL ISA meth2 od, we assessed the change of cytokines in plasma in patient s with digestive t ract cancer af ter chemother2 apy. Results Cytokines in plasma in patient s with digestive t ract cancer showed that the concent ration of IL22 was decreased with statistical significance in patient s with digestive t ract cancer compared with nor2 mal person, while the concent ration of IL210 and TNF2αcould be higher than those of normal person and without statistical significance. All the variations were related with clinical stage of tumor. One week af2 ter int ravenous chemotherapy in effective patient s with advanced digestive t ract cancer, the concent ration of IL22 was significantly decreased ; two weeks later, the concent ration of IL22 was recovered and closed to normal level ; three weeks later, it was even higher than the concent ration before chemotherapy. IL22 of patient s in non2effective group was slightly increased af ter chemotherapy but still lower than before. All the variations of IL210 and TNF2α af ter chemotherapy were showed the t rend declined af ter rising first . Conclusion Patient s with advanced2stage cancer have a poor immune response which was related with clinical stages of tumor. Af ter int ravenous chemotherapy, in early stage (about 122 weeks) patient s were both in an immunosuppressant state. While three weeks later, patient s with different result s showed different immune states. It may be followed by“rebound2overshoot”recovery of immune function in patient s with favorable clinical course.
Objective To investigate the change of cytokines in plasma af ter int ravenous chemotherapy in patient s with digestive t ract cancer and to discuss it s clinical significance. Methods Using EL ISA meth2 od, we assessed the change of cytokines in plasma in patient s with digestive t ract cancer af ter chemother2 apy. Results Cytokines in plasma in patient s with digestive t ract cancer showed that the concent ration of IL22 was decreased with statistical significance in patient s with digestive t ract cancer compared with nor2 mal person, while the concent ration of IL210 and TNF2αcould be higher than those of normal person and without statistical significance. All the variations were related with clinical stage of tumor. One week af2 ter int ravenous chemotherapy in effective patient s with advanced digestive t ract cancer, the concent ration of IL22 was significantly decreased ; two weeks later, the concent ration of IL22 was recovered and closed to normal level ; three weeks later, it was even higher than the concent ration before chemotherapy. IL22 of patient s in non2effective group was slightly increased af ter chemotherapy but still lower than before. All the variations of IL210 and TNF2α af ter chemotherapy were showed the t rend declined af ter rising first . Conclusion Patient s with advanced2stage cancer have a poor immune response which was related with clinical stages of tumor. Af ter int ravenous chemotherapy, in early stage (about 122 weeks) patient s were both in an immunosuppressant state. While three weeks later, patient s with different result s showed different immune states. It may be followed by“rebound2overshoot”recovery of immune function in patient s with favorable clinical course.
2008, 35(03): 201-203.
DOI: 10.3971/j.issn.1000-8578.3342
Abstract：
Objective To investigate the efficacy and safety of vinorelbine/ cisplatin (NP) with COX22 in2 hibitor (celecoxib) in the first2line t reatment of non2small cell lung cancer (NSCLC) . Methods Sixty pa2 tient s with NSCLC were randomly assigned to receive NP regimen with or without celecoxib 400 mg twice daily, for 2 cycles at least, meanwhile the expression of COX22 receptor f rom their specimen were detec2 ted by IHC. Results Response rate (RR) were 43. 3 % for patient s t reated with celecoxib and 40 % for those t reated with chemotherapy alone, Median survival time (MST) were 9. 8 and 9. 5 months respec2 tively( P > 0. 05) . The main toxicities in the two arms were nausea and vomitting, myelosuppression, without any significant difference. Conclusion Compared with NP alone, celecoxib combined with NP was not able to improve efficacy or prolong survival, nor did it increase toxicities.
Objective To investigate the efficacy and safety of vinorelbine/ cisplatin (NP) with COX22 in2 hibitor (celecoxib) in the first2line t reatment of non2small cell lung cancer (NSCLC) . Methods Sixty pa2 tient s with NSCLC were randomly assigned to receive NP regimen with or without celecoxib 400 mg twice daily, for 2 cycles at least, meanwhile the expression of COX22 receptor f rom their specimen were detec2 ted by IHC. Results Response rate (RR) were 43. 3 % for patient s t reated with celecoxib and 40 % for those t reated with chemotherapy alone, Median survival time (MST) were 9. 8 and 9. 5 months respec2 tively( P > 0. 05) . The main toxicities in the two arms were nausea and vomitting, myelosuppression, without any significant difference. Conclusion Compared with NP alone, celecoxib combined with NP was not able to improve efficacy or prolong survival, nor did it increase toxicities.
2008, 35(03): 204-206.
DOI: 10.3971/j.issn.1000-8578.3343
Abstract：
Objective To investigate the antitumor effect s and adverse reactions of gefitinib in t reating ad2 vanced non2small cell lung cancer. Methods Forty2two patient s who were right pathologically diagnosed with advanced non2small cell lung cancer and failed prior chemotherapy and radiotherapy were adminis2 tered orally with gefitinib 250 mg, once a day until cancer progressed or severe toxicity occurred. The ef2 ficacy adverse reactions of gefitinib survival and disease progression time of patient s were observed. Re2 sults Among the 42 patient s, 1 cases got complete response (CR), 13 partial response ( PR), 16 stable disease (SD) and 12 progression disease ( PD) . The total response rate was 33. 33 % and the disease con2 t rol rate was 71. 43 %. The median time to progression was 6. 0 months and the median survival time was 9. 2 months. The major adverse reactions of gefitinib included rash, itching and diarrhea. Conclusion Gefitinib was effective and safe for patient s with advanced non2small cell lung cancer who failed prior chemotherapy and radiotherapy. The toxicities of gefitinib were tolerable. Gefitinib is a good choice for the patient s with advanced non2small cell lung cancer who were resistant to chemotherapy and radiothera2 py.
Objective To investigate the antitumor effect s and adverse reactions of gefitinib in t reating ad2 vanced non2small cell lung cancer. Methods Forty2two patient s who were right pathologically diagnosed with advanced non2small cell lung cancer and failed prior chemotherapy and radiotherapy were adminis2 tered orally with gefitinib 250 mg, once a day until cancer progressed or severe toxicity occurred. The ef2 ficacy adverse reactions of gefitinib survival and disease progression time of patient s were observed. Re2 sults Among the 42 patient s, 1 cases got complete response (CR), 13 partial response ( PR), 16 stable disease (SD) and 12 progression disease ( PD) . The total response rate was 33. 33 % and the disease con2 t rol rate was 71. 43 %. The median time to progression was 6. 0 months and the median survival time was 9. 2 months. The major adverse reactions of gefitinib included rash, itching and diarrhea. Conclusion Gefitinib was effective and safe for patient s with advanced non2small cell lung cancer who failed prior chemotherapy and radiotherapy. The toxicities of gefitinib were tolerable. Gefitinib is a good choice for the patient s with advanced non2small cell lung cancer who were resistant to chemotherapy and radiothera2 py.
2008, 35(03): 207-209.
DOI: 10.3971/j.issn.1000-8578.3340
Abstract：
Objective To observe the efficacy and the side effect s of nedaplatin with fut raful in the t reat2 ment of advanced esophageal carcinoma. Methods Observing group NDP/ FT2207 regiment : given neda2 platin 80～100 mg/ m2 on day 1and fut raful 500～600 mg/ m2 on day 1 to 5 ; cont rol group :DDP/ 52Fu reg2 iment received cisplatin 80～100 mg/ m2 on day 1and 52Fluorouracil 500～750 mg/ m2 on day 1 to 5. In both groups per 28 days was a cycle, 2～3 cycles were one course. Results Response and toxicity could be assessed in all the 78 patient s, 42 patient s were in observing group, the other 36 patiest s were in con2 t rol group. The response rate of patient s t reated by NDP/ FT2207 and DDP/ 52Fu were 57. 1 % (24/ 42) and 50 % (18/ 36) respectively. The two groups have no significant difference. Conclusion The side effect s as gast rointestinal reactions and myelosuppression etal in observing group is lighter than that in cont rol group.
Objective To observe the efficacy and the side effect s of nedaplatin with fut raful in the t reat2 ment of advanced esophageal carcinoma. Methods Observing group NDP/ FT2207 regiment : given neda2 platin 80～100 mg/ m2 on day 1and fut raful 500～600 mg/ m2 on day 1 to 5 ; cont rol group :DDP/ 52Fu reg2 iment received cisplatin 80～100 mg/ m2 on day 1and 52Fluorouracil 500～750 mg/ m2 on day 1 to 5. In both groups per 28 days was a cycle, 2～3 cycles were one course. Results Response and toxicity could be assessed in all the 78 patient s, 42 patient s were in observing group, the other 36 patiest s were in con2 t rol group. The response rate of patient s t reated by NDP/ FT2207 and DDP/ 52Fu were 57. 1 % (24/ 42) and 50 % (18/ 36) respectively. The two groups have no significant difference. Conclusion The side effect s as gast rointestinal reactions and myelosuppression etal in observing group is lighter than that in cont rol group.
2008, 35(03): 209-211.
DOI: 10.3971/j.issn.1000-8578.3341
Abstract：
Objective To investigate the efficacy of DCEP2T regimen in t reatment of patient s with re2 lapsed or ref ractory multiple myeloma (MM) . Methods Twenty2eight patient s (19 male and 9 female, median age is 49 years) with ref ractory or relapsed myeloma had been t reated with DCEP2T for at least two cycles. The regimen consisted of 4 days of int ravenous dexamethasone (20～40) mg/ d, cyclophospha2 mide 200 mg/ d, etoposide 40 mg/ m2, cisplatin 10 mg/ m2, and daily thalidomide (100～200) mg/ d in a 42 week cycle. Results After two cycles of DCEP2T, 4 patient s (14. 3 %) achieved very good complete re2 sponse, and 14 patient s (50. 0 %) had a partial response. So the overall response rate was 64. 3 %. Among the 9 patient s with ext ramedullary evolvement, plasmacytoma completely disappeared in 4 patient s, and decreased markedly in 2 patient s, the response rate was 66. 7 %(6/ 9) . The most common nonhematologic toxicities were nausea and vomiting (32. 1 %), followed by constipation (25. 0 %) . Conclusion DCEP2T is an effective, tolerable, salvage combination chemotherapy for relapsed or ref ractory MM, as well as in ext ramedullary evolvement .
Objective To investigate the efficacy of DCEP2T regimen in t reatment of patient s with re2 lapsed or ref ractory multiple myeloma (MM) . Methods Twenty2eight patient s (19 male and 9 female, median age is 49 years) with ref ractory or relapsed myeloma had been t reated with DCEP2T for at least two cycles. The regimen consisted of 4 days of int ravenous dexamethasone (20～40) mg/ d, cyclophospha2 mide 200 mg/ d, etoposide 40 mg/ m2, cisplatin 10 mg/ m2, and daily thalidomide (100～200) mg/ d in a 42 week cycle. Results After two cycles of DCEP2T, 4 patient s (14. 3 %) achieved very good complete re2 sponse, and 14 patient s (50. 0 %) had a partial response. So the overall response rate was 64. 3 %. Among the 9 patient s with ext ramedullary evolvement, plasmacytoma completely disappeared in 4 patient s, and decreased markedly in 2 patient s, the response rate was 66. 7 %(6/ 9) . The most common nonhematologic toxicities were nausea and vomiting (32. 1 %), followed by constipation (25. 0 %) . Conclusion DCEP2T is an effective, tolerable, salvage combination chemotherapy for relapsed or ref ractory MM, as well as in ext ramedullary evolvement .
